You are here: Home » Reuters » News
Business Standard

J&J quarterly profit beats on demand for cancer drugs


(Reuters) - Johnson & Johnson reported a better-than-expected first-quarter profit on Tuesday and raised its full-year sales forecast, helped by growing demand for its cancer drugs.J&J's pharmaceuticals sales rose 3.8 percent to $3.04 billion, driven by sales of its cancer drugs such as Darzalex, Imbruvica and Zytiga that rose 45 percent to $2.31 billion in the quarter.J&J raised its full-year sales forecast to $81.0 billion to $81.8 billion from its previous forecast of $80.6 billion to $81.4 billion.Excluding items, the company earned $2.06 per share. Analysts on average were expecting ...

This article is no longer available in our repository.

There could be multiple reasons for this.

First Published: Tue, April 17 2018. 17:04 IST